Blueprint Medicines

This week, our offices worldwide will be closed for our annual Global Summer Well-Being Shutdown. We take our people-first approach seriously and recognize the importance of nurturing a healthy work-life balance. This is the first of two week-long shutdowns we offer each year to provide time to recharge and rest. Thank you to the #BlueCrew for your relentless drive and unwavering commitment to patients throughout the year. For now, we're out of office, so we'll see you next week!

Since our founding, we've worked closely with patient communities to ensure our programs incorporate real-world insights and positively impact the patients we serve. From early development through commercialization, we dedicate time to engaging with patients to hear their perspectives, collaborating with patient advocacy groups, creating educational programs, and more. At Blueprint Medicines, patients are our priority as we strive to improve and extend people's lives globally.

After more than a decade studying systemic mastocytosis (SM), we've built a deep understanding of mast cells and their role in driving several allergic/inflammatory diseases. We also recognize the KIT receptor as a key regulator of mast cell activation, proliferation, and survival.   Using our innovative scientific platform that drives continued discovery of novel therapies, along with our proven ability to inhibit the KIT D816V mutation in SM, we aim to apply our knowledge to other mast cell-driven diseases. Learn how below:

"He promised me that if I came to Blueprint, I'd find a warm and welcoming environment that would help me develop a skillset in clinical development." Mentors, advisors and support networks serve as an essential part of shaping one's career path. Listen in as Benjamin Lampson, Medical Director, and Javier I. Muñoz Gonzalez, Ph.D., Director of Clinical Development, recount their journeys to Blueprint Medicines and places they've found supportive environments for professional growth. We're proud that our talented #BlueCrew is comprised of people across multiple disciplines, united by our goal to advance innovative therapies that improve and extend patients' lives.

This month, we attended GreenRoots, Inc.'s Evening on the Creek event to celebrate 30 years of their fight for environmental justice, greater quality of life and improved public health. At Blueprint Medicines, we believe human health is inextricably linked with our environment, and responsible stewardship is an important part of our mission to help patients live better lives. By approaching this mission alongside organizations who focus on these efforts every day, we can advance our environmental sustainability goals in a meaningful way. Learn more in our latest Sustainability Report: https://bit.ly/3VaO15r

Our core value of Patients First runs through our entire organization, and our Patient Affairs team helps us uphold this promise every day. Their role in building strong, trusting relationships with the advocacy community drives our interactions with patients and helps us deliver treatments that address their needs. Read more from Paul Lim, Director, Patient Affairs on how his team works at the intersection of the patient community’s needs and Blueprint’s aspirations:

Join us at #EHA2024! In an oral presentation, we’re sharing data from our PATHFINDER clinical study with a median follow-up of more than three years, and we’re presenting results from our PRISM Survey that highlight patient and healthcare provider perspectives on the burden of systemic mastocytosis. These data reflect our ongoing partnership with the SM community to advance treatment and address patient needs across the spectrum of the disease.  

Happy Pride! This #PrideMonth, we hosted our annual networking event with OUTbio, the biotech industry’s largest LGBTQ+ professionals group. The event also highlighted organizations/individuals such as BAGLY, Inc., Dani Bernstein, Fenway Health, Stonewall Sports, Inc. Boston, The Nova Comedy Collective and The Theater Offensive. With these partnerships, we collectively spark dialogue, broaden perspectives and strengthen connections. We believe in everyone's right to show up as their authentic selves, and we're committed to creating inclusive spaces that empower our LGBTQ+ community and allies.

Congratulations to our CEO Kate Haviland for joining the Board of Directors at Biotechnology Innovation Organization (BIO). As the world’s largest advocacy association for biotechnology companies, academic and research institutions, and related organizations globally, BIO represents a significant platform for industry leadership. We're proud to see Kate expand her influence in our industry to help drive further innovation and growth.

What could be the toll of living with indolent systemic mastocytosis (ISM)? ISM could mean facing a range of recurring symptoms that can affect every aspect of life. Chronic bone pain, allergic reactions, and constant fatigue are often invisible but profoundly real. We're dedicated to understanding and alleviating the burden of ISM to help improve patients' lives.